Human Medications, Human Drugs, Animal Medications, Animal Drugs, Pharmacy law, Pharmaceutical law, Compounding law, Sterile and Non Sterile Compounding 797 Compliance, Veterinary law, Veterinary Compounding Law; Health Care; Awareness of all Types of Compounding Issues; Pharmacy Benefit Managers (PBMs), Outsourcing Facilities Food and Drug Administration and Compliance Issues
Thursday, April 24, 2014
Plaintiffs Seek to Keep Clinics in Tainted Steroid MDL
Read more: http://www.nationallawjournal.com/id=1202649240978/Plaintiffs-Seek-to-Keep-Clinics-in-Tainted-Steroid-MDL#ixzz2zraybRhY
How Topical Compounding Has Worked For My Patients
How Topical Compounding Has Worked For My Patients: Allen Jacobs, DPM FACFAS
Source: PodiatryToday.com
You may have noticed the increasing presentation of the subject of topical compounded medications at our podiatry meetings. The reason for this is that the science of topical pharmaceutical compounding has advanced significantly over recent years.
Topical compounding allows the local delivery of high doses of medication to an area of pathology. Examples include the treatment of Achilles tendinosis, plantar fasciitis or following an acute injury. This technique provides the delivery of medications locally at levels significantly higher than with the administration of the same medications given systemically, typically as orals. In addition, the utilization of topical compounded medications provides for lower systemic levels of the same medication administered orally, generally less than 5 percent of the serum levels when one administers the same medications systemically. Furthermore, given the low systemic levels of the medications when administered topically, drug interactions are far less likely to occur.
Topical compounded medications expand the ability of the podiatric physician to effectively treat a variety of problems commonly encountered in daily practice. Many podiatric physicians are reluctant to utilize systemic medications for fear of adverse sequella or drug interactions, as a result denying some patients optimal efforts at pain relief or the reduction of inflammation. In addition, topically compounded medications are frequently accepted by the “I am already taking too many medications” patient and the ‘needle-phobic’ patient.
A particular aspect of topical compounded medications is the fact that they are medication(s), allowing me to combine multiple agents with multiple mechanisms of action. As a result, my ability to provide a patient with pain relief is substantially greater.
quoted from here
Source: PodiatryToday.com
You may have noticed the increasing presentation of the subject of topical compounded medications at our podiatry meetings. The reason for this is that the science of topical pharmaceutical compounding has advanced significantly over recent years.
Topical compounding allows the local delivery of high doses of medication to an area of pathology. Examples include the treatment of Achilles tendinosis, plantar fasciitis or following an acute injury. This technique provides the delivery of medications locally at levels significantly higher than with the administration of the same medications given systemically, typically as orals. In addition, the utilization of topical compounded medications provides for lower systemic levels of the same medication administered orally, generally less than 5 percent of the serum levels when one administers the same medications systemically. Furthermore, given the low systemic levels of the medications when administered topically, drug interactions are far less likely to occur.
Topical compounded medications expand the ability of the podiatric physician to effectively treat a variety of problems commonly encountered in daily practice. Many podiatric physicians are reluctant to utilize systemic medications for fear of adverse sequella or drug interactions, as a result denying some patients optimal efforts at pain relief or the reduction of inflammation. In addition, topically compounded medications are frequently accepted by the “I am already taking too many medications” patient and the ‘needle-phobic’ patient.
A particular aspect of topical compounded medications is the fact that they are medication(s), allowing me to combine multiple agents with multiple mechanisms of action. As a result, my ability to provide a patient with pain relief is substantially greater.
quoted from here
Report from April 2014 NM Racing Commission Meeting--issue of compounding preparations at racetrack was tabled for further discussion
The New Mexico Racing Commission held its monthly meeting at its headquarters in Albuquerque on Thursday, April 17.
New Mexico Horse Breeders’ Association executive director Anna Fay Davis gave the commission her race-a-day report for Sunland Park, which opened its 76-day season on December 6. During the first 72 days of the meet, the track ran 354 New Mexico-bred races -- 247 for Thoroughbreds and 107 for Quarter Horses. By comparison, Sunland Park carded 348 state-bred races -- 245 for Thoroughbreds and 103 for Quarter Horses -- during the first 72 days of its 2012-13 season.
An average of 4.92 New Mexico-bred races per day were run during the first 72 days of the Sunland Park meet, an increase of 1.7 percent over the 4,84 state-bred races per day contested during the first 72 days of the track’s 2012-13 season.
Also, during the first 63 days of the 2013-14 Sunland Park meet, a total of 484 New Mexico-breds competed in open overnight races, of which 126 (26 percent) finished first, second, or third. Of this total, 49 were Thoroughbreds and 77 were Quarter Horses. Bonuses totaling $98,916.10 were paid to the owners of these horses.
By comparison, 468 state-breds raced in open overnight races during the first 63 days of the 2012-13 Sunland meet, of which 96 (21 percent) finished first, second or third.
Also at the meeting, commissioner Ray Willis of Roswell, chairman of the NMRC medication committee, reported on the committee’s meeting on April 16. Willis said that the main topic of discussion was the acceptable levels of corticosteroids recently established by the Association of Racing Commissioners International.
“The RCI set standards of corticosteroids that might be acceptable for Thoroughbreds and Standardbreds, but at the meeting several veterinarians suggested we do our own studies on levels for Quarter Horses, which are a big part of our industry in New Mexico,” Willis said. “We’re going to have another meeting as soon as possible, before our next regular commission meeting in May, and kick around some ideas what what we can do.”
The issue of compounding agencies at racetracks was tabled for further discussion.
“This was the best-attended medication meeting I’ve ever been to, and it was a very productive meeting,” Willis said. “Hopefully, we can build on what was discusssed.”
continue to read here
New Mexico Horse Breeders’ Association executive director Anna Fay Davis gave the commission her race-a-day report for Sunland Park, which opened its 76-day season on December 6. During the first 72 days of the meet, the track ran 354 New Mexico-bred races -- 247 for Thoroughbreds and 107 for Quarter Horses. By comparison, Sunland Park carded 348 state-bred races -- 245 for Thoroughbreds and 103 for Quarter Horses -- during the first 72 days of its 2012-13 season.
An average of 4.92 New Mexico-bred races per day were run during the first 72 days of the Sunland Park meet, an increase of 1.7 percent over the 4,84 state-bred races per day contested during the first 72 days of the track’s 2012-13 season.
Also, during the first 63 days of the 2013-14 Sunland Park meet, a total of 484 New Mexico-breds competed in open overnight races, of which 126 (26 percent) finished first, second, or third. Of this total, 49 were Thoroughbreds and 77 were Quarter Horses. Bonuses totaling $98,916.10 were paid to the owners of these horses.
By comparison, 468 state-breds raced in open overnight races during the first 63 days of the 2012-13 Sunland meet, of which 96 (21 percent) finished first, second or third.
Also at the meeting, commissioner Ray Willis of Roswell, chairman of the NMRC medication committee, reported on the committee’s meeting on April 16. Willis said that the main topic of discussion was the acceptable levels of corticosteroids recently established by the Association of Racing Commissioners International.
“The RCI set standards of corticosteroids that might be acceptable for Thoroughbreds and Standardbreds, but at the meeting several veterinarians suggested we do our own studies on levels for Quarter Horses, which are a big part of our industry in New Mexico,” Willis said. “We’re going to have another meeting as soon as possible, before our next regular commission meeting in May, and kick around some ideas what what we can do.”
The issue of compounding agencies at racetracks was tabled for further discussion.
“This was the best-attended medication meeting I’ve ever been to, and it was a very productive meeting,” Willis said. “Hopefully, we can build on what was discusssed.”
continue to read here
Subscribe to:
Posts (Atom)